Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023 Post published:February 24, 2023 Post category:Press Release
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Post published:February 24, 2023 Post category:Press Release
Transcend Therapeutics announces Series A funding round of $40 million Post published:February 23, 2023 Post category:Press Release
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Post published:February 22, 2023 Post category:Press Release
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds Post published:February 22, 2023 Post category:Press Release
Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor Post published:February 21, 2023 Post category:Press Release
AIMS v. DEA: Advocating for Open Access to Psilocybin Assisted Therapy Post published:February 21, 2023 Post category:2022 Year in Review